JP2019517586A - カッパオピオイド受容体アゴニストの持続放出組成物 - Google Patents

カッパオピオイド受容体アゴニストの持続放出組成物 Download PDF

Info

Publication number
JP2019517586A
JP2019517586A JP2019516085A JP2019516085A JP2019517586A JP 2019517586 A JP2019517586 A JP 2019517586A JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019517586 A JP2019517586 A JP 2019517586A
Authority
JP
Japan
Prior art keywords
sustained release
substituted
release composition
pain
kappa opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517586A5 (enExample
Inventor
ガネカール、ゴータム
Original Assignee
ジェイティー ファーマスーティカルズ、インク．
ジェイティー ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェイティー ファーマスーティカルズ、インク．, ジェイティー ファーマスーティカルズ、インク． filed Critical ジェイティー ファーマスーティカルズ、インク．
Publication of JP2019517586A publication Critical patent/JP2019517586A/ja
Publication of JP2019517586A5 publication Critical patent/JP2019517586A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019516085A 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物 Pending JP2019517586A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345583P 2016-06-03 2016-06-03
US62/345,583 2016-06-03
PCT/US2017/035874 WO2017210668A1 (en) 2016-06-03 2017-06-05 Sustained release compositions of kappa-opioid receptor agonist

Publications (2)

Publication Number Publication Date
JP2019517586A true JP2019517586A (ja) 2019-06-24
JP2019517586A5 JP2019517586A5 (enExample) 2020-07-27

Family

ID=60478002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516085A Pending JP2019517586A (ja) 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物

Country Status (5)

Country Link
US (1) US20200316159A1 (enExample)
EP (1) EP3463306A4 (enExample)
JP (1) JP2019517586A (enExample)
CN (1) CN109789094A (enExample)
WO (1) WO2017210668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
CN114615976A (zh) 2019-08-07 2022-06-10 人福医药美国公司 κ阿片受体肽酰胺激动剂
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
JP7577265B2 (ja) 2020-06-25 2024-11-05 ヒューマンウェル ファーマシューティカル ユーエス，インコーポレイテッド 医学的障害の治療のためのペプチド
US12616732B2 (en) 2020-06-25 2026-05-05 Yichang Humanwell Pharmaceuticals Co., Ltd. Peptides for treatment of medical disorders
EP4322982A4 (en) * 2021-04-14 2025-03-19 Titan Pharmaceuticals, Inc. Kappa-opioid receptor agonist implants for treatment of pruritus
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
CN114873741B (zh) * 2022-05-31 2023-03-14 南京大学 一种脱氮缓释碳源材料及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528422A (ja) * 2002-05-31 2005-09-22 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
JP2009538310A (ja) * 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド 哺乳動物におけるプロラクチンを上昇させる方法
JP2010509343A (ja) * 2006-11-10 2010-03-25 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
JP2010534192A (ja) * 2007-05-01 2010-11-04 フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー 鎮痛化合物
JP2013241447A (ja) * 2006-11-10 2013-12-05 Cara Therapeutics Inc 合成ペプチドアミドおよびその二量体
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534847T3 (es) * 2010-09-02 2015-04-29 Grünenthal GmbH Forma de dosificación inviolable que comprende un polímero aniónico

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528422A (ja) * 2002-05-31 2005-09-22 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
JP2009538310A (ja) * 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド 哺乳動物におけるプロラクチンを上昇させる方法
JP2010509343A (ja) * 2006-11-10 2010-03-25 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
JP2013241447A (ja) * 2006-11-10 2013-12-05 Cara Therapeutics Inc 合成ペプチドアミドおよびその二量体
JP2010534192A (ja) * 2007-05-01 2010-11-04 フンダサオ・デ・アムパロ・ア・ペスキーサ・ド・エスタド・デ・サン・パウロ−エフイ・ア・ペー・エ・エシ・ペー 鎮痛化合物
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE OPEN MEDICINAL CHEMISTRY JOURNAL, 2013, VOL.7, PP.16-22, JPN6021020825, ISSN: 0004947325 *

Also Published As

Publication number Publication date
WO2017210668A1 (en) 2017-12-07
EP3463306A4 (en) 2020-03-11
US20200316159A1 (en) 2020-10-08
CN109789094A (zh) 2019-05-21
EP3463306A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
US20200316159A1 (en) Sustained release compositions of kappa-opioid receptor agonist
KR20210134313A (ko) 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법
WO2019036430A1 (en) METHODS OF TREATING HEPATIC DISEASES
KR20140041457A (ko) 신경 장애 치료용 신규 조성물
US10561618B2 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
US20090143335A1 (en) Modified absorption formulation of gaboxadol
JP2020524702A (ja) 免疫応答を調節するｇａｂａの能力の強化
CN102065865B (zh) 多发性骨髓瘤治疗
CN116726178A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
JP5757544B2 (ja) 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法
KR20170101907A (ko) 흑색종 치료에 사용하기 위한 아필리모드
WO2022268825A1 (en) Phenyl pyrrole aminoguanidine salts and formulations
EP2968475A2 (en) Acth for treatment of acute respiratory distress syndrome
TWI606826B (zh) 艾拉莫德或其鹽之用途
JP2012501301A (ja) ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
CN100493512C (zh) 一种含氢氯噻嗪和盐酸可乐定的缓释制剂及其制备方法
US20200188379A1 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
US20230129787A1 (en) Methods for treating ovarian cancer
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
TW200911247A (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease
WO2000069436A1 (en) Methods of using and compositions comprising n-desmethylzolpidem
CN100467064C (zh) 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
JP5440502B2 (ja) 過敏性腸症候群の治療方法
CN112469410A (zh) 药物化合物在治疗亨廷顿病中的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220923

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221220